文献速递类风湿关节炎

早期类风湿关节炎影像学关节损伤:托珠单抗与甲氨蝶呤达标治疗策略比较

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

U-Act-Early 试验纳入 317 例新诊断未用 DMARD 的 RA 患者,随机起始托珠单抗、甲氨蝶呤逐步加量或两者联合的达标治疗。52 周和 104 周摄片评分显示,JSN 进展在各策略间无差异;侵蚀进展在 104 周时两个托珠单抗组均显著低于 MTX 组,主要见于足部。

要点

  • 104 周侵蚀进展两个托珠单抗组均显著低于 MTX 组(p≤0.023)。
  • 足部侵蚀进展在 104 周两个托珠单抗组均更低(P≤0.046),手部无差异。
  • JSN 进展在两个时间点各策略间均无差异(P≥0.09)。

核心结论

  • 在未用 DMARD 的早期 RA 患者中,起始托珠单抗为基础的达标治疗策略较起始 MTX 逐步加量策略更能抑制侵蚀进展,尤其足部。

研究设计与样本

  • U-Act-Early 试验,317 例新诊断未用 DMARD 的 RA 患者随机接受托珠单抗、MTX 逐步加量或两者联合。
  • 基线及 52、104 周采用 Sharp-van der Heijde 侵蚀与 JSN 评分摄片。
  • 比较各策略组自基线变化及无影像学进展(变化≤0)患者比例。

主要发现

  • 全研究人群侵蚀与 JSN 评分平均变化:52 周分别为 0.59 和 0.18,104 周分别为 0.70 和 0.50。
  • JSN 进展在两个时间点各策略间无差异(P≥0.09)。
  • 侵蚀进展在 104 周两个托珠单抗组均显著低于 MTX 组(p≤0.023)。
  • 104 周足部侵蚀进展两个托珠单抗组均更低(P≤0.046),手部无差异(P≥0.11)。
  • 无侵蚀进展比例:52 周托珠单抗联合 MTX 87%(P=0.038)、托珠单抗 81%(P=0.29),MTX 组 74%;104 周分别为 85%(P=0.001)、77%(P=0.028),MTX 组 60%。

关键数值与推荐

  • 无影像学进展定义为自基线变化≤0。
  • 影像学评分采用 Sharp-van der Heijde 侵蚀与 JSN 评分。

临床怎么用

  • 对未用 DMARD 的早期 RA 患者,起始托珠单抗为基础的达标治疗可能更有利于抑制侵蚀进展,尤其足部。
  • JSN 进展在各策略间无差异,提示不同策略对 JSN 影响有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands in the U-Act-Early trial. METHODS: In this trial, 317 newly diagnosed DMARD-naïve RA patients initiated randomly tocilizumab, or step-up MTX or a combination of the two. Radiographs were scored at baseline and after 52 and 104 weeks using the Sharp-van der Heijde erosion and JSN score. Between the strategy arms, changes from baseline and the proportions of patients without radiographic progression (change from baseline ≤0) were compared. RESULTS: Mean changes from baseline in erosion and JSN scores for the whole study population were after 52 weeks 0.59 and 0.18 and after 104 weeks 0.70 and 0.50, respectively. For JSN, at both time points no differences in progression were found between strategies (P ⩾ 0.09). For erosions, the progression was significantly lower at week 104 in both tocilizumab arms when compared with the MTX arm ((p≤0.023). Less progression of erosions in the feet was found after 104 weeks in both tocilizumab arms (P ⩽ 0.046); this was not significant for the hands (P ⩾ 0.11). The proportion of patients without progression in erosions was higher in the tocilizumab arms at week 52 (tocilizumab plus MTX: 87%, P = 0.038; tocilizumab: 81%, P = 0.29) and 104 (tocilizumab plus MTX: 85%, P = 0.001; tocilizumab: 77%, P = 0.028), compared with the MTX arm (74 and 60%, respectively). CONCLUSION: In DMARD-naïve early RA patients, initiating a tocilizumab-based treat-to-target strategy inhibits the progression of erosions, especially in the feet, more compared with initiation of a step-up MTX strategy. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01034137.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Teitsma XM, Jacobs JWG, Welsing PMJ, et al. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatology (Oxford). 2018. PMID: 29095992. doi:10.1093/rheumatology/kex386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。